Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > LABS seems like a no brainer heading into 2024
View:
Post by mdjbrown on Apr 08, 2024 9:46am

LABS seems like a no brainer heading into 2024

Several catalysts beyond Medipharm’s control that could add a bump to the share price near term

ANVISA approvals
Canadian Federal excise tax cuts
DEA rescheduling announcement
Generic Epidiolex announcements
Any of the current ongoing Trial updates
Increased global Dronbinol orders in first quarter
Reveal of Medipharm’s international partner
Reputable Global Analyst coverage
Q1 improvements to bottom line
Take over announcement
Comment by subaru1i on Apr 08, 2024 9:51am
Absolutely correct mdj.  My only question for the new age romans who think they rule the world at this juncture of accerlating plague and pestilence, why did this happen over 30 years ago?  Perhaps the new age romans can consult with the resident senators from Pompei of their old age ancestors.  
Comment by QContinuum1 on Apr 08, 2024 9:55am
Don't disagree but your list isn't ranked on likelihood, and impact is even more different than that.  That said, even those in the likely category drive ought drive the SP to many multiples from here. Likely ANVISA approvals Reveal of Medipharm’s international partner DEA rescheduling announcement Increased global Dronbinol orders in first quarter Q1 improvements to bottom line ...more  
Comment by Starkicker on Apr 08, 2024 10:03am
I would expect the mid-May earnings report reveals at least one of the likely/possible points on your list, as well as at least a 30% uptick in revenue from Q1 2023, otherwise it will be a disappointment.
Comment by QContinuum1 on Apr 08, 2024 12:02pm
Last call, they stated that Brazil approval was expected Q2 (so any time now) and one could also then expect that their Brazil partner will be announced. With the seemingly positive inspection behind them, you have to believe that a Brazil announcement is the next most likely and positive influencer to come.
Comment by okgonow on Apr 09, 2024 9:13am
Agree Star ..... thets the only most likely thing to happen.... the other stuff ar just possibilities of a scale of 0-100% to happen  everyone has to decide for themselves where MPL lands when it comes to those possibilites and when they will have an actual effect on the bottom line of the balance sheet!!! The bottom line of the balance sheet is the only indicator of a companys health ...more  
Comment by Lvlchange on Apr 09, 2024 9:44am
When does the report come out?  Need $$$$
Comment by okgonow on Apr 09, 2024 9:49am
Q1 ?   May sometime??!
Comment by Starkicker on Apr 09, 2024 10:02am
Q1 2024 will be mid-May as per MDJ's post a few weeks ago. Q2 mid August and Q3 mid November. Q4 and annual mid March.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities